Several biomarkers such as NGAL, KIM-1, L-FABP, or IL-18 are able to exclude the ATN-AKI with great accuracy; however, for some of them the exact specificity and sensitivity remain unclear and emphasize the need for further studies on different populations. This evidence concerns the gene LCN2 and acute kidney injury.